As Alto Neuroscience’s machine learning-derived, biomarker-based depression therapies accrue positive phase 2 data, the company is planning to join the growing trickle of biotechs aiming to IPO in early 2024.The Los Altos, Calif.-based drug developer has applied to list on the New York Stock Exchange under the ticker “ANRO,” although the biotech has yet to […]
